1.Kidd, D, Burton, B, Plant, GT, Graham, EM. Chronic relapsing inflammatory optic neuropathy (CRION). Brain. February 2003; 126(Pt 2): 276–84.
2.Petzold, A, Pittock, S, Lennon, V, Maggiore, C, Weinshenker, BG, Plant, GT. Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatr. January 2010; 81(1): 109–11.
3.Rodriguez, M, Siva, A, Cross, SA, O’Brien, PC, Kurland, LT. Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology [Internet]. February 1995; 45(2): 244–50. Available from: http://www.neurology.org/content/45/2/244.short?sid=5d3bc217-394e-46d0-a720-df8704457287//www.neurology.org
4.Beck, RW, Cleary, PA, Anderson, MM, Keltner, JL, Shults, WT, Kaufman, DI, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. February 27, 1992; 326(9): 581–8.
5.Optic Neuritis Study Group. The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. December 1991; 109(12): 1673–8.
6.Trobe, JD, Beck, RW, Moke, PS, Cleary, PA. Contrast sensitivity and other vision tests in the optic neuritis treatment trial. Am J Ophthalmol. May 1996; 121(5): 547–53.
7.Keltner, JL, Johnson, CA, Spurr, JO, Beck, RW. Baseline visual field profile of optic neuritis. The experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Arch Ophthalmol. February 1993; 111(2): 231–4.
8.Cox, TA, Thompson, HS, Corbett, JJ. Relative afferent pupillary defects in optic neuritis. Am J Ophthalmol. November 1, 1981; 92(5): 685–90.
9.Beck, RW, Cleary, PA. Optic neuritis treatment trial. One-year follow-up results. Arch Ophthalmol. June 1993; 111(6): 773–5.
10.la Cruz de, J, Kupersmith, MJ. Clinical profile of simultaneous bilateral optic neuritis in adults. British Journal of Ophthalmology. May 2006; 90(5): 551–4.
11.Beck, RW, Kupersmith, MJ, Cleary, PA, Katz, B. Fellow eye abnormalities in acute unilateral optic neuritis. Experience of the optic neuritis treatment trial. Ophthalmology. May 1993; 100(5): 691–8.
12.Ormerod, IE, McDonald, WI. Multiple sclerosis presenting with progressive visual failure. J Neurol Neurosurg Psychiatr. September 1, 1984; 47(9): 943–6.
13.Ashworth, B. Chronic retrobulbar and chiasmal neuritis. British Journal of Ophthalmology. October 1967; 51(10): 698–702.
14.Hoyt, WF, Schlicke, B, Eckelhoff, RJ. Fundoscopic appearance of a nerve-fibre-bundle defect. British Journal of Ophthalmology. August 1972; 56(8): 577–83.
15.Frisén, L, Hoyt, WF. Insidious atrophy of retinal nerve fibers in multiple sclerosis. Funduscopic identification in patients with and without visual complaints. Arch Ophthalmol. August 1, 1974; 92(2): 91–7.
16.Sharpe, JA, Sanders, MD. Atrophy of myelinated nerve fibres in the retina in optic neuritis. British Journal of Ophthalmology. Aprl 1, 1975; 59(4): 229–32.
17.Elbøl, P, Work, K. Retinal nerve fiber layer in multiple sclerosis. Acta Ophthalmology. August 1, 1990; 68(4): 481–6.
18.MacFadyen, DJ, Drance, SM, Douglas, GR, Airaksinen, PJ, Mawson, DK, Paty, DW. The retinal nerve fiber layer, neuroretinal rim area, and visual evoked potentials in MS. Neurology [Internet]. September 1, 1988; 38(9): 1353–8. Available from: http://neurology.org/content/38/9/1353.short
19.Quigley, HA, Addicks, EM. Quantitative studies of retinal nerve fiber layer defects. Arch Ophthalmology. May 1982; 100(5): 807–14.
20.Parisi, V, Manni, G, Spadaro, M, Colacino, G, Restuccia, R, Marchi, S, et al. Correlation between morphological and functional retinal impairment in multiple sclerosis patients. Invest Ophthalmol Vis Sci. October 1999; 40(11): 2520–7.
21.Trip, SA, Schlottmann, PG, Jones, SJ, Altmann, DR, Garway-Heath, DF, Thompson, AJ, et al. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol. September 2005; 58(3): 383–91.
22.Costello, F, Hodge, W, Pan, Y, Eggenberger, E, Coupland, S, Kardon, R. Tracking retinal nerve fiber layer loss after optic neuritis: a prospective study using optical coherence tomography. Multiple Sclerosis. June 23, 2008; 14(7): 893–905.
23.Lange, AP, Sadjadi, R, Zhu, F, Alkabie, S, Costello, F, Traboulsee, AL. Spectral-domain optical coherence tomography of retinal nerve fiber layer thickness in NMO patients. J Neuroophthalmol [Internet]. September 2013; 33(3): 213–9. Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=23863782&retmode=ref&cmd=prlinks
24.Bichuetti, DB, Oliveira, EML, Souza, NA, Rivero, RLM, Gabbai, AA. Neuromyelitis optica in Brazil: a study on clinical and prognostic factors. Multiple Sclerosis. May 2009; 15(5): 613–9.
25.Fisher, J, Jacobs, D, Markowitz, C, Galetta, S, Volpe, N, Nanoschiavi, M, et al. Relation of Visual Function to Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis. Ophthalmology. February 2006; 113(2): 324–32.
26.Costello, F, Coupland, S, Hodge, W, Lorello, GR, Koroluk, J, Pan, YI, et al. Quantifying axonal loss after optic neuritis with optical coherence tomography. Annals of Neurology. June 1, 2006; 59(6): 963–9.
27.Albrecht, P, Fröhlich, R, Hartung, H-P, Kieseier, BC, Methner, A. Optical coherence tomography measures axonal loss in multiple sclerosis independently of optic neuritis. J Neurol. November 9, 2007; 254(11): 1595–6.
28.Pulicken, M, Gordon-Lipkin, E, Balcer, LJ, Frohman, E, Cutter, G, Calabresi, PA. Optical coherence tomography and disease subtype in multiple sclerosis. Neurology. November 27, 2007; 69(22): 2085–92.
29.Pueyo, V, Martin, J, Fernandez, J, Almarcegui, C, Ara, J, Egea, C, et al. Axonal loss in the retinal nerve fiber layer in patients with multiple sclerosis. Multiple Sclerosis. June 2008; 14(5): 609–14.
30.Zaveri, MS, Conger, A, Salter, A, Frohman, TC, Galetta, SL, Markowitz, CE, et al. Retinal imaging by laser polarimetry and optical coherence tomography evidence of axonal degeneration in multiple sclerosis. Arch Neurol. July 2008; 65(7): 924–8.
31.Klistorner, A, Arvind, H, Nguyen, T, Garrick, R, Paine, M, Graham, S, et al. Axonal loss and myelin in early ON loss in postacute optic neuritis. Ann Neurol. September 2008; 64(3): 325–31.
32.Siger, M, Dziegielewski, K, Jasek, L, Bieniek, M, Nicpan, A, Nawrocki, J, et al. Optical coherence tomography in multiple sclerosis: thickness of the retinal nerve fiber layer as a potential measure of axonal loss and brain atrophy. J Neurol. October 2008; 255(10): 1555–60.
33.Frohman, EM, Dwyer, MG, Frohman, T, Cox, JL, Salter, A, Greenberg, BM, et al. Relationship of optic nerve and brain conventional and non-conventional MRI measures and retinal nerve fiber layer thickness, as assessed by OCT and GDx: a pilot study. J Neurol Sci. July 15, 2009; 282(1–2): 96–105.
34.Ratchford, JN, Quigg, ME, Conger, A, Frohman, T, Frohman, E, Balcer, LJ, et al. Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology. July 28, 2009; 73(4): 302–8.
35.Burkholder, BM, Osborne, B, Loguidice, MJ, Bisker, E, Frohman, TC, Conger, A, et al. Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis. Arch Neurol. November 2009; 66(11): 1366–72.
36.Garcia-Martin, E, Pueyo, V, Ara, J, Almarcegui, C, Martin, J, Pablo, L, et al. Effect of optic neuritis on progressive axonal damage in multiple sclerosis patients. Mult Scler [Internet]. June 20, 2011 Jun 20; 17(7): 830–7. Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=21300734&retmode=ref&cmd=prlinks
37.Syc, SB, Saidha, S, Newsome, SD, Ratchford, JN, Levy, M, Ford, E, et al. Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain. February 2012; 135(Pt 2): 521–33.
38.Costello, F, Hodge, W, Pan, YI, Burton, JM, Freedman, MS, Stys, PK, et al. Sex-specific differences in retinal nerve fiber layer thinning after acute optic neuritis. Neurology. October 2012; 79(18): 1866–72.
40.Gelfand, JM, Nolan, R, Schwartz, DM, Graves, J, Green, AJ. Microcystic macular edema in multiple sclerosis is associated with disease severity. Brain. June 2012; 135(Pt 6): 1786–93.
41.Saidha, S, Sotirchos, ES, Ibrahim, MA, Crainiceanu, CM, Gelfand, JM, Sepah, YJ, et al. Microcystic macular edema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet Neurol. October 4, 2012; 11(11): 963–72.
42.Balk, LJ, Killestein, J, Polman, CH, Uitdehaag, BMJ, Petzold, A. Microcystic macular edema confirmed, but not specific for multiple sclerosis. Brain. December 18, 2012; 135(12): e226–6.
43.Kaufhold, F, Zimmermann, H, Schneider, E, Ruprecht, K, Paul, F, Oberwahrenbrock, T, et al. Optic neuritis is associated with inner nuclear layer thickening and microcystic macular edema independently of multiple sclerosis. PLoS ONE. 2013; 8(8): e71145.
44.Abegg, M, Zinkernagel, M, Wolf, S. Microcystic macular degeneration from optic neuropathy. Brain. December 18, 2012; 135(12): 225–5.
45.van Buren, JM. Trans-synaptic retrograde degeneration in the visual system of primates. J Neurol Neurosurg Psychiatr. October 1963; 26: 402–9.
46.Kaushik, M, Wang, CY, Barnett, MH, Garrick, R, Parratt, J, Graham, SL, et al. Inner nuclear layer thickening is inversley proportional to retinal ganglion cell loss in optic neuritis. PLoS ONE. 2013; 8(10): e78341.
47.Kerrison, JB, Flynn, T, Green, WR. Retinal pathologic changes in multiple sclerosis. Retina (Philadelphia, Pa). 1994; 14(5): 445–51.
48.Green, AJ, McQuaid, S, Hauser, SL, Allen, IV, Lyness, R. Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration. Brain. June 2010; 133(Pt 6): 1591–601.
49.Pro, MJ, Pons, ME, Liebmann, JM, Ritch, R, Zafar, S, Lefton, D, et al. Imaging of the optic disc and retinal nerve fiber layer in acute optic neuritis. J Neurol Sci. December 1, 2006; 250(1–2): 114–9.
50.Henderson, APD, Altmann, DR, Trip, AS, Kallis, C, Jones, SJ, Schlottmann, PG, et al. A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials. Brain. September 2010; 133(9): 2592–602.
51.Hickman, SJ, Toosy, AT, Jones, SJ, Altmann, DR, Miszkiel, KA, MacManus, DG, et al. A serial MRI study following optic nerve mean area in acute optic neuritis. Brain. November 2004; 127(Pt 11): 2498–505.
52.Garas, A, Simó, M, Holló, G. Nerve fiber layer and macular thinning measured with different imaging methods during the course of acute optic neuritis. European Journal of Ophthalmology. October 22, 2010.
53.Henderson, APD, Altmann, DR, Trip, SA, Miszkiel, KA, Schlottmann, PG, Jones, SJ, et al. Early factors associated with axonal loss after optic neuritis. Ann Neurol. December 21, 2011; 70(6): 955–63.
54.Khaleeli, Z, Ciccarelli, O, Manfredonia, F, Barkhof, F, Brochet, B, Cercignani, M, et al. Predicting progression in primary progressive multiple sclerosis: a 10-year multicenter study. Ann Neurol. June 2008; 63(6): 790–3.
55.Koch, M, Kingwell, E, Rieckmann, P, Tremlett, H, UBC MS Clinic Neurologists. The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatr. September 2010; 81(9): 1039–43.
56.Lucchinetti, CF, Mandler, RN, McGavern, D, Brück, W, Gleich, G, Ransohoff, RM, et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain. July 2002; 125(Pt 7): 1450–61.
57.Parratt, JD, Prineas, JW. Neuromyelitis optica: a demyelinating disease characterized by acute destruction and regeneration of perivascular astrocytes. Mult Scler. September 30, 2010; 16(10): 1156–72.
58.Lennon, VA, Wingerchuk, DM, Kryzer, TJ, Pittock, SJ, Lucchinetti, CF, Fujihara, K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. November 2004; 364(9451): 2106–12.
59.Lennon, VA, Kryzer, TJ, Pittock, SJ, Verkman, AS, Hinson, SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. August 15, 2005; 202(4): 473–7.
60.Wingerchuk, DM, Hogancamp, WF, O’Brien, PC, Weinshenker, BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology. 1999; 53(5): 1107–14.
61.O’Riordan, JI, Gallagher, HL, Thompson, AJ, Howard, RS, Kingsley, DP, Thompson, EJ, et al. Clinical, CSF, and MRI findings in Devic’s neuromyelitis optica. J Neurol Neurosurg Psychiatr. April 1996; 60(4): 382–7.
62.Papais-Alvarenga, RM, Carellos, SC, Alvarenga, MP, Holander, C, Bichara, RP, Thuler, LCS. Clinical course of optic neuritis in patients with relapsing neuromyelitis optica. Arch Ophthalmol. January 2008; 126(1): 12–6.
63.Rivera, JF, Kurtzke, JF, Booth, VJA, Corona, T V. Characteristics of Devic’s disease (neuromyelitis optica) in Mexico. J Neurol. May 2008; 255(5): 710–5.
64.Nakamura, M, Nakazawa, T, Doi, H, Hariya, T, Omodaka, K, Misu, T, et al. Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica. Graefes Arch Clin Exp Ophthalmol. December 2010; 248(12): 1777–85.
65.Bichuetti, DB, de Camargo, AS, Falcão, AB, Gonçalves, FF, Tavares, IM, de Oliveira, EML. The retinal nerve fiber layer of patients with neuromyelitis optica and chronic relapsing optic neuritis is more severely damaged than patients with multiple sclerosis. J Neuroophthalmol [Internet]. September 2013; 33(3): 220–4. Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=23917443&retmode=ref&cmd=prlinks
66.Fernandes, DB, Raza, AS, Nogueira, RGF, Wang, D, Callegaro, D, Hood, DC, et al. Evaluation of inner retinal layers in patients with multiple sclerosis or neuromyelitis optica using optical coherence tomography. Ophthalmology. February 2013; 120(2): 387–94.
67.Sotirchos, ES, Saidha, S, Byraiah, G, Mealy, MA, Ibrahim, MA, Sepah, YJ, et al. In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology [Internet]. April 8, 2013; 80(15): 1406–14. Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=23516321&retmode=ref&cmd=prlinks
68.de Seze, J, Blanc, F, Jeanjean, L, Zéphir, H, Labauge, P, Bouyon, M, et al. Optical coherence tomography in neuromyelitis optica. Arch Neurol. July 2008; 65(7): 920–3.
69.Merle, H, Olindo, S, Donnio, A, Richer, R, Smadja, D, Cabre, P. Retinal peripapillary nerve fiber layer thickness in neuromyelitis optica. Invest Ophthalmol Vis Sci. October 2008; 49(10): 4412–7.
70.Naismith, RT, Tutlam, NT, Xu, J, Klawiter, EC, Shepherd, J, Trinkaus, K, et al. Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology. March 24, 2009; 72(12): 1077–82.
71.Green, AJ, Cree, BAC. Distinctive retinal nerve fibre layer and vascular changes in neuromyelitis optica following optic neuritis. J Neurol Neurosurg Psychiatr. September 2009; 80(9): 1002–5.
72.Bouyon, M, Collongues, N, Zéphir, H, Ballonzoli, L, Jeanjean, L, Lebrun, C, et al. Longitudinal follow-up of vision in a neuromyelitis optica cohort. Mult Scler [Internet]. August 30, 2013; 19(10): 1320–2. Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=23413296&retmode=ref&cmd=prlinks
73.Compston, A. Mechanisms of axon-glial injury of the optic nerve. Eye. November 2004; 18(11): 1182–7.
74.Kolappan, M, Henderson, APD, Jenkins, TM, Wheeler-Kingshott, CAM, Plant, GT, Thompson, AJ, et al. Assessing structure and function of the afferent visual pathway in multiple sclerosis and associated optic neuritis. J Neurol. March 2009; 256(3): 305–19.
75.Esfahani, MR, Harandi, ZA, Movasat, M, Nikdel, M, Adelpour, M, Momeni, A, et al. Memantine for axonal loss of optic neuritis. Graefes Arch Clin Exp Ophthalmol. June 2012; 250(6): 863–9.
76.Tsakiri, A, Kallenbach, K, Fuglø, D, Wanscher, B, Larsson, H, Frederiksen, J. Simvastatin improves final visual outcome in acute optic neuritis: a randomized study. Mult Scler. January 2012; 18(1): 72–81.
77.Jepson, S, Vought, B, Gross, CH, Gan, L, Austen, D, Frantz, JD, et al. LINGO-1, a transmembrane signaling protein, inhibits oligodendrocyte differentiation and myelination through intercellular self-interactions. J Biol Chem. June 22, 2012; 287(26): 22184–95.
78.Mi, S, Pepinsky, RB, Cadavid, D. Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic. CNS Drugs. July 2013; 27(7): 493–503.
79.Canessa, CM, Horisberger, JD, Rossier, BC. Epithelial sodium channel related to proteins involved in neurodegeneration. Nature. February 4, 1993; 361(6411): 467–70.
80.Black, JA, Waxman, SG. Phenytoin protects central axons in experimental autoimmune encephalomyelitis. J Neurol Sci. November 15, 2008; 274(1–2): 57–63.